Your browser is no longer supported. Please, upgrade your browser.
RGEN Repligen Corporation daily Stock Chart
RGEN [NASD]
Repligen Corporation
Index- P/E223.71 EPS (ttm)0.44 Insider Own0.80% Shs Outstand51.42M Perf Week6.12%
Market Cap5.05B Forward P/E76.91 EPS next Y1.28 Insider Trans-18.07% Shs Float48.20M Perf Month4.76%
Income21.40M PEG9.50 EPS next Q0.22 Inst Own84.20% Short Float5.47% Perf Quarter5.90%
Sales270.20M P/S18.69 EPS this Y19.10% Inst Trans0.00% Short Ratio4.98 Perf Half Y30.27%
Book/sh20.34 P/B4.83 EPS next Y23.98% ROA1.80% Target Price112.13 Perf Year72.42%
Cash/sh10.28 P/C9.56 EPS next 5Y23.55% ROE2.40% 52W Range52.87 - 109.94 Perf YTD6.17%
Dividend- P/FCF103.70 EPS past 5Y12.10% ROI2.00% 52W High-10.67% Beta0.97
Dividend %- Quick Ratio12.10 Sales past 5Y33.60% Gross Margin55.90% 52W Low85.76% ATR6.75
Employees761 Current Ratio13.30 Sales Q/Q33.90% Oper. Margin11.20% RSI (14)54.78 Volatility4.49% 8.20%
OptionableYes Debt/Eq0.22 EPS Q/Q-44.00% Profit Margin7.90% Rel Volume1.27 Prev Close96.95
ShortableYes LT Debt/Eq0.22 EarningsFeb 20 BMO Payout0.00% Avg Volume530.19K Price98.21
Recom1.50 SMA205.72% SMA502.05% SMA20010.27% Volume671,264 Change1.30%
Mar-23-20Reiterated H.C. Wainwright Buy $110 → $100
Nov-15-19Initiated Stifel Buy
Nov-01-19Upgrade First Analysis Sec Outperform → Strong Buy $107 → $110
Oct-15-19Initiated SVB Leerink Outperform $100
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Feb-13-17Upgrade Piper Jaffray Neutral → Overweight
Feb-22-16Initiated Craig Hallum Buy
Nov-06-15Downgrade Jefferies Buy → Hold
Apr-23-15Reiterated Jefferies Buy $25 → $38
Mar-07-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Apr-01-20 06:00AM  Novavax and Regeneron- Speculating on Vaccines MoneyShow
Mar-21-20 11:30AM  Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report? Zacks
Mar-19-20 04:17PM  IBD 50 Stocks To Watch: This Biotech Supplier Shows Spiking Relative Strength Investor's Business Daily -9.62%
Mar-12-20 10:58AM  Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet? Simply Wall St.
Feb-28-20 11:10AM  This Week On IBD Live (Feb. 28) Investor's Business Daily Video
Feb-27-20 07:30AM  Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors GlobeNewswire
Feb-21-20 10:32AM  Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat Zacks
Feb-20-20 11:50PM  Edited Transcript of RGEN earnings conference call or presentation 20-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -7.35%
08:45AM  Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates Zacks
07:30AM  Repligen Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
07:06AM  The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga
Feb-19-20 12:45PM  Repligen (RGEN) is an Incredible Growth Stock: 3 Reasons Why Zacks
Feb-13-20 12:31PM  Earnings Preview: Repligen (RGEN) Q4 Earnings Expected to Decline Zacks
Feb-06-20 07:30AM  Repligen to Report Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-04-20 06:41PM  Should Growth Investors Buy this Cancer Screening Biotech Stock? Zacks
Jan-30-20 11:10AM  Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks
Jan-24-20 10:15AM  Breakout Stocks & Technical Analysis Investor's Business Daily
Jan-17-20 08:45AM  ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-10-20 12:43PM  Investors Who Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago Are Now Up 289% Simply Wall St.
Jan-08-20 04:06PM  Stocks To Watch: Life Sciences Leader Repligen Tests New Buy With 84% Growth Investor's Business Daily
Jan-07-20 07:30AM  Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-19 02:04PM  A Look At The Fair Value Of Repligen Corporation (NASDAQ:RGEN) Simply Wall St.
Dec-09-19 11:30AM  Has Repligen (RGEN) Outpaced Other Medical Stocks This Year? Zacks
Dec-08-19 07:11PM  Hedge Funds Have Never Been This Bullish On Repligen Corporation (RGEN) Insider Monkey
Dec-06-19 12:45PM  3 Reasons Growth Investors Will Love Repligen (RGEN) Zacks
Dec-04-19 12:00PM  Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy Zacks
Dec-02-19 04:32PM  Hedge Funds Hit The Bullseye With This Stock Pick Insider Monkey
Nov-14-19 09:30AM  Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year? Zacks
Nov-06-19 04:08AM  Edited Transcript of RGEN earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
Nov-01-19 02:49PM  Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks +6.64%
Oct-31-19 09:15AM  Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates Zacks
07:30AM  Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance GlobeNewswire
Oct-30-19 11:49AM  Does Repligen Corporation's (NASDAQ:RGEN) CEO Pay Matter? Simply Wall St.
Oct-24-19 03:34PM  Hedge Funds Have Never Been More Bullish On Repligen Corporation (RGEN) Insider Monkey
10:32AM  Repligen (RGEN) Reports Next Week: What to Expect Zacks
Oct-23-19 10:29AM  Repligen to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-03-19 07:54PM  Edited Transcript of RGEN earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Sep-30-19 11:12AM  Does The Repligen Corporation (NASDAQ:RGEN) Share Price Fall With The Market? Simply Wall St.
Sep-24-19 05:38PM  Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes CNW Group
Sep-23-19 06:41AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Sep-14-19 06:31AM  3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-11-19 07:15PM  Repligen Corp (RGEN) CEO Anthony Hunt Sold $996,546 of Shares GuruFocus.com
Sep-09-19 02:19PM  Here's Why Repligen Has Dropped as Much as 13.1% Today Motley Fool -11.66%
Sep-06-19 06:00PM  S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600 PR Newswire
Aug-30-19 06:47AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Aug-28-19 07:11AM  3 Stocks to Buy and Hold for Decades Motley Fool
Aug-27-19 03:16PM  With EPS Growth And More, Repligen (NASDAQ:RGEN) Is Interesting Simply Wall St.
Aug-16-19 07:11AM  3 Growth Stocks for In-the-Know Investors Motley Fool
Aug-08-19 10:13AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Aug-05-19 10:39AM  Repligen Grows Revenue 48% in Q2 Motley Fool
06:37AM  With A 3.0% Return On Equity, Is Repligen Corporation (NASDAQ:RGEN) A Quality Stock? Simply Wall St.
Aug-02-19 11:54AM  Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks -5.13%
10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
02:24AM  Repligen (RGEN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 12:02PM  Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks
12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
09:25AM  Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates Zacks
07:30AM  Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance GlobeNewswire
07:02AM  Powell Gives Space for Growth, Market Overreacts: 5 Picks Zacks
Jul-30-19 10:58AM  The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center Zacks
Jul-29-19 07:58AM  5 Top Picks on Three Key Takeaways From Q2 U.S. GDP Zacks
Jul-25-19 11:25AM  Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View Zacks
10:33AM  Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Jul-23-19 04:01PM  Repligen to Report Second Quarter 2019 Financial Results GlobeNewswire
10:56AM  Is a Beat in Store for Repligen (RGEN) This Earnings Season? Zacks
Jul-19-19 07:42PM  Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters Options GlobeNewswire
09:30AM  Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-18-19 11:18AM  NuCana Initiates Dosing in Phase I Study for Solid Tumors Zacks
Jul-17-19 08:10AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
12:14AM  Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024 GlobeNewswire
Jul-15-19 04:02PM  Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes GlobeNewswire
Jul-13-19 07:28AM  These 6 stocks in the S&P 1500 have more than doubled in 12 months MarketWatch
Jul-12-19 09:25AM  Repligen Corporation (NASDAQ:RGEN): Financial Strength Analysis Simply Wall St.
Jul-11-19 02:05PM  Edited Transcript of RGEN earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
12:10PM  Here's Why Repligen Gained 62.9% in the First Half of 2019 Motley Fool
Jul-09-19 09:54AM  Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100 Zacks
08:45AM  Here is Why Growth Investors Should Buy Repligen (RGEN) Now Zacks
Jul-05-19 09:21AM  The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products Zacks
Jul-03-19 09:12AM  U.S. Economy Likely to Sustain Longest Expansion: 5 Top Picks Zacks
Jul-02-19 05:09PM  Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx Zacks
Jun-27-19 10:18AM  Inovio Up on Enrollment Closure in Cervical Dysplasia Study Zacks
Jun-26-19 06:17PM  Pacira Gets EMA Acceptance for Pain Management Drug Exparel Zacks
06:11AM  Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin Zacks
Jun-21-19 09:52AM  Repligen Corporation (RGEN) Shares March Higher, Can It Continue? Zacks
Jun-20-19 09:35AM  Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study Zacks
Jun-19-19 09:40AM  Intrexon Up on Striking 100M Cannabinoid Deal With Surterra Zacks
08:31AM  Wall Street Foresees a Fed Rate Cut: Winners & Losers Zacks
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-13-19 10:26AM  NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag Zacks
Jun-12-19 01:24PM  How Many Repligen Corporation (NASDAQ:RGEN) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
10:30AM  Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks
Jun-10-19 06:06PM  Athenex Rallies on Positive Early Data on Psoriasis Candidate Zacks
08:45AM  Looking for a Growth Stock? 3 Reasons Why Repligen (RGEN) is a Solid Choice Zacks
08:00AM  Investment Opportunities Easier To Find After Market Pullback, Says Neuberger Berman's Ken Turek Investor's Business Daily
Jun-06-19 10:33AM  BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady Zacks
10:29AM  Reata's (RETA) Kidney Candidate Gets Orphan Drug Status Zacks
Jun-05-19 09:44AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne Zacks
Jun-04-19 05:30PM  Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR Zacks +5.63%
02:12PM  5 Biotech Stocks to Buy Right Now Zacks
10:03AM  Repligen to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cox JohnDirectorMar 24Sale96.721,858179,706923Mar 26 07:31 PM
Cox JohnDirectorMar 18Option Exercise24.3726,736651,60329,517Mar 20 04:25 PM
Cox JohnDirectorMar 18Sale95.2726,7362,547,0352,781Mar 20 04:25 PM
RYAN THOMAS F JRDirectorMar 16Option Exercise40.421,00040,4152,923Mar 18 05:10 PM
RYAN THOMAS F JRDirectorMar 16Sale91.481,00091,4801,923Mar 18 05:10 PM
RYAN THOMAS F JRDirectorMar 04Option Exercise41.704,796200,0156,719Mar 05 05:53 PM
Cox JohnDirectorMar 04Option Exercise12.9110,000129,10012,781Mar 05 05:52 PM
Hunt AnthonyChief Executive OfficerMar 04Sale90.1312,3001,108,599230,241Mar 05 05:50 PM
Cox JohnDirectorMar 04Sale93.3910,000933,9002,781Mar 05 05:52 PM
Snodgres JonChief Financial OfficerMar 04Sale90.391,04594,45836,127Mar 05 05:53 PM
RYAN THOMAS F JRDirectorMar 04Sale88.824,796425,9811,923Mar 05 05:53 PM
KURIYEL RALFSenior VP, R&DMar 04Sale90.762,555231,88826,524Mar 05 05:53 PM
KURIYEL RALFSenior VP, R&DMar 03Sale88.3545039,75829,079Mar 05 05:53 PM
RYAN THOMAS F JRDirectorMar 03Sale85.722,225190,7271,923Mar 05 05:53 PM
Snodgres JonChief Financial OfficerMar 03Sale88.1861053,79037,172Mar 05 05:53 PM
Hunt AnthonyChief Executive OfficerMar 03Sale88.222,190193,194242,541Mar 05 05:50 PM
KURIYEL RALFSenior VP, R&DFeb 26Sale86.6019516,88726,313Feb 27 05:38 PM
Snodgres JonChief Financial OfficerFeb 26Sale86.221,10094,83731,096Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 26Sale86.513,475300,627226,148Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 25Option Exercise25.0321,945549,190231,148Feb 27 05:39 PM
Hunt AnthonyChief Executive OfficerFeb 25Sale91.5611,7351,074,447219,413Feb 27 05:39 PM
Cox JohnDirectorFeb 24Sale92.814,455413,4552,781Feb 26 04:27 PM
DAWES KAREN ADirectorFeb 21Sale98.704,000394,793113,034Feb 24 05:51 PM
Snodgres JonChief Financial OfficerDec 05Option Exercise25.273,95799,98032,196Dec 09 04:17 PM
Hunt AnthonyChief Executive OfficerSep 19Option Exercise16.5520,000331,000223,013Sep 23 06:02 PM
Hunt AnthonyChief Executive OfficerSep 19Sale82.893,600298,390219,413Sep 23 06:02 PM
Hunt AnthonyChief Executive OfficerSep 09Sale82.4012,094996,521203,013Sep 11 04:58 PM
DAWES KAREN ADirectorJun 17Option Exercise4.9620,00099,200118,329Jun 19 07:00 PM
DAWES KAREN ADirectorJun 17Sale77.351,295100,168117,034Jun 19 07:00 PM
COOPER GLENN L MDDirectorMay 23Sale66.945,000334,71535,709May 28 04:17 PM